Key takeaways
- BTIG analyst Marie Thibault has raised the price target for Haemonetics to $142.00, indicating a potential 16.5% upside from the current share price.
- The company reported strong financial results, with adjusted earnings reaching $1.35 per share and revenue climbing to $357.76 million, both surpassing analyst expectations.
- Haemonetics shares have demonstrated significant market outperformance, rising 25.3% over the past month and 59.00% year-to-date, exceeding sector and industry benchmarks.
Haemonetics (NYSE: HAE) makes products used to collect blood and plasma and support hospital procedures. BTIG analyst Marie Thibault raises its price target to $142.00. At the $121.89 share price cited with the announcement, that target is about 16.5% higher. A price target is an analyst’s estimate, not a guaranteed future price.
The new target follows a strong run for Haemonetics. Shares rise 25.3% over the past month and 59.00% year to date, as highlighted by Zacks Investment Research. That year-to-date gain exceeds the Zacks Medical sector’s 11.4% rise, while the Medical–Products industry is down 10.9%.
Haemonetics’ recent results provide context for the target. Adjusted earnings reach $1.35 per share for the quarter ended September 2026, above the $1.30 analyst estimate and up from $1.27 a year earlier. Revenue rises to $357.76 million from $327.32 million, beating estimates by 3.15%, as highlighted by Zacks Investment Research.
Haemonetics beats analyst estimates for both earnings and revenue in each of the past four quarters. Analysts expect earnings of $5.29 per share for the current fiscal year, a 6.65% increase. These estimates help explain what investors may weigh against Thibault’s $142.00 target.
